LCM
KYMR icon

Legato Capital Management’s Kymera Therapeutics KYMR Stock Holding History

Legato Capital Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$958K Buy
8,354
+3,492
+72% +$300K 0.08% 360
2026
Q1 		$405K Sell
4,862
-4,672
-49% -$370K 0.04% 573
2025
Q4 		$742K Buy
9,534
+2,751
+41% +$186K 0.06% 438
2025
Q3 		$384K Buy
+6,783
New +$306K 0.04% 475

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Legato Capital Management's KYMR Position: Q2 2026 in Review

Legato Capital Management increased its Kymera Therapeutics (KYMR) stake by 72% in Q2 2026, buying an estimated $300K and bringing the position to 8,354 shares worth $958K. The position accounts for 0.08% of the portfolio, ranked #360.

Legato Capital Management first reported a position in KYMR in Q3 2025 and has held it in 4 quarters since. 276 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Legato Capital Management held 8,354 shares of Kymera Therapeutics worth $958K as of Q2 2026.
  • Legato Capital Management bought 3,492 Kymera Therapeutics shares in Q2 2026, an estimated $300K.
  • Kymera Therapeutics made up 0.08% of Legato Capital Management's portfolio in Q2 2026, its #360 holding.
  • Legato Capital Management first reported a position in Kymera Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 276 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Legato Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.